In a recent issue of this journal, Bolwell et al 1 reported the results of a randomized study comparing three strategies for administering G-CSF to patients submitted to autologous progenitor cell transplants. Seventy patients were randomized to receive G-CSF (5 g/kg) starting either at days 0, ϩ3 or ϩ5. There was no difference in the outcome variables among the three groups. We would like to report a similar experience.
Between March 1996 and March 1998 we performed 30 autologous peripheral blood progenitor cell transplantations. The underlying diseases were as follows: multiple myeloma (10), non-Hodgkin's lymphoma (nine), Hodgkin's disease (five) and breast cancer (six). Twenty-eight patients received G-CSF (5 g/kg daily): the first 11 patients received G-CSF at day ϩ1 (group one) and the other 17 patients received it at day ϩ5 (group two). The two groups were well balanced with respect to the underlying diagnoses, age, conditioning regimens and the total number of CD34 ϩ cells infused. As shown in Table 1 , there was no difference in the outcome variables between the two groups. The median duration of G-CSF use was 11 days (7-25) in group one and seven days (5-13) in group two (P = 0.007). The median duration of neutropenia was 10 days (6-14) in group one and nine days (5-20) in group two (P = 0.72). Likewise, the times to neutrophil and platelet engraftment were similar in both groups. The time to neutrophil engraftment was influenced by the number of CFU-GM and CD34 cells infused (P = 0.03 for both comparisons, linear regression analysis).
It is conceivable that G-CSF would confer an advantage
The above correspondence was shown to Dr Bolwell who replied as follows:
Maiolino et al confirm our report that G-CSF may be delayed until day ϩ5 after autologous peripheral blood progenitor cell transplantation without compromising neutrophil or platelet engraftment. We found no difference in platelet or neutrophil engraftment when beginning G-CSF on day 0, day ϩ3, or day ϩ5, and concluded that beginning on day ϩ5 resulted in comparable engraftment and achieved significant cost savings. Maiolino et al had similar results when comparing G-CSF on day ϩ1 vs G-CSF beginning day ϩ5.
The limitation of circulating Aspergillus antigen detection methods for BMT recipients
We would like to comment on the article, 'Comparison of an enzyme immunoassay and a latex agglutination system Neutrophil and platelet engraftments strongly correlate with the number of progenitor cells infused. Maiolino questions whether the enhanced neutrophil engraftment seen with G-CSF post-transplantation occurs largely in those patients receiving low numbers of progenitor cells. It may be that those patients receiving very high numbers of progenitor cells would have rapid engraftment with or without growth factors post-transplant. This is an interesting question and one worthy of additional study.
for the diagnosis of invasive aspergillosis in bone marrow transplant recipients', by Machetti et al in the May 1998 issue of Bone Marrow Transplantation.
1 The authors compared the efficacy of the two circulating antigen detection methods (latex agglutination test (LA) and enzyme-linked immunosorbent assay (ELISA)) for the diagnosis of invasive aspergillosis after BMT. The following two questions are raised concerning the sensitivity and the false-positive
